Global Insulin Delivery Systems Market Growth 2023-2029
An insulin pump is a medical device used for the administration of insulin in the treatment of diabetes mellitus, also known as continuous subcutaneous insulin therapy. The device configuration may vary depending on design. A traditional pump includes: the pump (including controls, processing module, and batteries), a disposable reservoir for insulin (inside the pump) and a disposable infusion set, including a cannula for subcutaneous insertion (under the skin) and a tubing system to connect the insulin reservoir to the cannula.
LPI (LP Information)' newest research report, the “Insulin Delivery Systems Industry Forecast” looks at past sales and reviews total world Insulin Delivery Systems sales in 2022, providing a comprehensive analysis by region and market sector of projected Insulin Delivery Systems sales for 2023 through 2029. With Insulin Delivery Systems sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Insulin Delivery Systems industry.
This Insight Report provides a comprehensive analysis of the global Insulin Delivery Systems landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Insulin Delivery Systems portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Insulin Delivery Systems market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Insulin Delivery Systems and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Insulin Delivery Systems.
The global Insulin Delivery Systems market size is projected to grow from US$ 13680 million in 2022 to US$ 19000 million in 2029; it is expected to grow at a CAGR of 19000 from 2023 to 2029.
An insulin pump is an alternative to multiple daily injections of insulin by insulin syringes or an insulin pen and allows for flexible insulin therapy when used in conjunction with blood glucose monitoring and carbohydrate counting.
This report presents a comprehensive overview, market shares, and growth opportunities of Insulin Delivery Systems market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Insulin Pens
Insulin Pumps
Insulin Syringes
Segmentation by application
Homecare
Hospitals & Clinics
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Becton, Dickinson and Company
Novo Nordisk
Medtronic
Sanofi
ELI Lilly and Company
Ypsomed Holding
Animas Corporation
Tandem Diabetes Care
Insulet Corporation
Biocon
Key Questions Addressed in this Report
What is the 10-year outlook for the global Insulin Delivery Systems market?
What factors are driving Insulin Delivery Systems market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Insulin Delivery Systems market opportunities vary by end market size?
How does Insulin Delivery Systems break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
Please note: The report will take approximately 2 business days to prepare and deliver.